We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 6 of 8 for:    "glycogen storage disease type I"

Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03181399
Recruitment Status : Not yet recruiting
First Posted : June 8, 2017
Last Update Posted : March 13, 2018
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
University of Texas Southwestern Medical Center

Brief Summary:
Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in addition to IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuropsychological and neurological performance indices in children and adults genetically diagnosed with G1D receiving a regular diet at enrollment.

Condition or disease Intervention/treatment Phase
GLUT1DS1 Epilepsy Glut1 Deficiency Syndrome 1, Autosomal Recessive Glucose Metabolism Disorders Glucose Transport Defect Glucose Transporter Type 1 Deficiency Syndrome Glucose Transporter Protein Type 1 Deficiency Syndrome Drug: Triheptanoin Phase 2

Detailed Description:
This is an open-label, single arm trial of orally-administered C7 in G1D. Subjects will replace a fixed percentage of their daily caloric intake (based on the results of Protocol 1) with C7 for 6 months, undergo full evaluation and discontinuation of treatment at a 6 month visit, and return for an off-treatment follow up visit 3 months after C7 oil discontinuation, for total duration of participation of 9 months. Subjects will undergo treatment initiation on a 24-hour inpatient basis. During that 24-hr inpatient treatment initiation, subjects will have continuous EEG both to monitor for real-time seizure activity (for safety) and to determine EEG changes (secondary outcome) before, during, and after treatment initiation. Subjects will undergo clinical evaluation, comprehensive blood work, ataxia scale rating, EEG, and neuropsychological testing at baseline, 6 months, and 9 months.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Intervention Model Description: All subjects will receive supplementation at the maximum tolerated dose.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D)
Anticipated Study Start Date : May 30, 2018
Estimated Primary Completion Date : May 30, 2020
Estimated Study Completion Date : May 30, 2023

Arm Intervention/treatment
Single arm study
This is a single arm study.
Drug: Triheptanoin
. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
Other Name: C7

Primary Outcome Measures :
  1. Neuropsychological attention scores [ Time Frame: Medication taken daily for 6 months. ]
    To evaluate the impact of triheptanoin supplementation on measures of neuropsychological function primarily indicative of attention in G1D subjects receiving normal diet. These measures include one of two quantitative scales WPPSI-IV (Wechsler Preschool and Primary Scale of Intelligence; if younger than 7 years old), or WASI-II (Wechsler Abbreviated Scale of Intelligence; if older than 8 years old) depending on age.

Secondary Outcome Measures :
  1. EEG changes: spike-wave activity duration in EEG (electroencephalogram) tracings [ Time Frame: Medication taken daily for 6 months. ]
    Expecting to find a greater than 30% decrease in spike-wave activity determined as percent duration of spike-wave activity over the total duration of EEG.

  2. Ataxia scores [ Time Frame: Medication taken daily for 6 months. ]

    Ataxia is scored 0 (normal; no ataxia) to 30 (severe ataxia) per modified ICARS ( International Cooperative Ataxia Rating Scale) scale in Schmahmann, J. D., Gardner, R., MacMore, J. and Vangel, M. G. (2009), Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS.

    Mov. Disord., 24: 1820-1828

  3. Global impression scale [ Time Frame: Medication taken daily for 6 months. ]
    Scores range from 1 (very much improved) through to 7 (very much worse)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of glucose transporter type I deficiency (G1D), confirmed by clinical genotyping at a CLIA-certified laboratory or by PET scan.
  • Stable diet on no dietary therapy (i.e., no dietary therapy for 1 month).
  • Males and females 30 months to 17 years 11 months old, inclusive.

Exclusion Criteria:

  • Subjects with evidence of independent, unrelated metabolic and/or genetic disease.
  • Subjects with a chronic gastrointestinal disorder, such as irritable bowel syndrome, Crohn's disease, or colitis that could increase the subject's risk of developing diarrhea or stomach pain.
  • Subjects with a BMI (body mass index) greater than or equal to 30.
  • Subjects currently on dietary therapy (i.e., ketogenic diet, medium chain triglyceride supplemented diets, Atkins diet and versions of it, low glycemic index diet, and related diets).
  • Subjects with no evidence of abnormal EEG (spike wave discharges) in the last 12 months.
  • Women who are pregnant or breast-feeding may not participate. Women who plan to become pregnant during the course of the study, or who are unwilling to use birth control to prevent pregnancy (including abstinence) may not participate. Females age 10 and over will be asked to provide a urine sample for a pregnancy test via dipstick. Subjects will be asked to agree to abstinence or another form of birth control for the duration of the study.
  • Allergy/sensitivity to C7.
  • Previous use of triheptanoin in the past 1 month. Subjects who participate in Protocol 1 of this study are thus eligible.
  • Subjects exhibiting signs of dementia, or diagnosed with any degenerative brain disorder (such as Alzheimer's disease) that would confound assessment of cognitive changes, in the opinion of the investigator.
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of subject or legal guardian/representative to give written informed consent, or assent for children age 10-17.
  • Addition of a new antiseizure drug in the previous 3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03181399

Contact: Juan Pascual, MD 214-648-5155 rare.diseases@utsouthwestern.edu
Contact: Adrian Avila, BS 214-648-5155 rare.diseases@utsouthwestern.edu

United States, Texas
University of Texas Southwestern Medical Center Not yet recruiting
Dallas, Texas, United States, 75390
Contact: Juan Pascual, MD    214-648-5155    rare.diseases@utsouthwestern.edu   
Contact: Adrian Avila, BS    214-648-5155    rare.diseases@utsouthwestern.edu   
Sponsors and Collaborators
University of Texas Southwestern Medical Center
National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Juan Pascual, MD Study Principal Investigator

Responsible Party: University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT03181399     History of Changes
Other Study ID Numbers: Protocol 2
1R01NS094257-01A1 ( U.S. NIH Grant/Contract )
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: March 13, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Metabolic Diseases
Glucose Metabolism Disorders
Carbohydrate Metabolism, Inborn Errors
Glycogen Storage Disease Type I
Pathologic Processes
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Glycogen Storage Disease